格林用于心脏骤停后昏迷中的神经保护:一项随机临床试验
Sjoukje Nutma1,2, Albertus Beishuizen3, Walter M van den Bergh4
1Department of Clinical Neurophysiology, Technical Medical Center, University of Twente, Enschede, the Netherlands.
JAMA neurology
|May 6, 2024
概括
在昏迷的心脏骤停患者中,用乙格列林治疗显示出改善神经结果的潜力,并且是安全的. 需要进一步的第三阶段试验来证实这些发现,用于心脏骤停后的护理.
科学领域:
- 神经学 神经学
- 关键护理医学 关键护理医学
- 心脏病学 心脏病学
背景情况:
- 医院外心脏骤停后的生存率有所增加,但神经学结果仍然不理想.
- 现有的神经保护策略在昏迷状态的心脏骤停幸存者中没有显示出明确的有效性.
- 在临床前模型中,acyl-ghrelin表现出神经保护作用,在人体研究中表现出安全性.
研究的目的:
- 评估静脉注射乙格林在改善心脏骤停后昏迷患者的神经结果方面的安全性和潜在疗效.
- 评估乙格雷林对神经恢复和生存率在这个患者群体的影响.
主要方法:
- 一个第二阶段,双盲,安慰剂控制,随机临床试验 (GRECO) 涉及160名成年昏迷的心脏骤停患者.
- 患者除了接受标准护理外,还可以接受静脉注射乙格雷林 (600微克每天两次,持续7天) 或安慰剂.
- 主要结局是6个月的大脑性能类别 (CPC) 规模得分;次要结局包括死亡率和神经元特异性酶 (NSE) 水平.
主要成果:
- 乙格列林治疗显示出改善CPC得分的趋势 (OR 1.78,P=.06) 和在第一天显著降低NSE水平 (P=.04).
- 与安慰剂 (51%) 相比,乙格雷林组的死亡率较低 (37%),尽管在统计学上不显著 (P=.08).
- 严重不良事件的发生率和类型在乙格林和安慰剂组之间是相似的,这表明了有利的安全性.
结论:
- 静脉注射的乙格林似乎是安全的,并且可能有效地改善心脏骤停后昏迷患者的神经结果.
- 虽然结果表明潜在的益处,但需要更大的第三期试验来确定最终的疗效并指导临床实践.
相关概念视频
01:15Hypoglycemia and Glucagon
257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
01:30Regulation of Food Intake
224
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
224
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422